For almost 20 years Fasken Martineau Stringer Saul have advised clients in the Life Sciences sector on a full range of transactions including mergers, acquisitions, fundraisings, listings, rights issues, licensing agreements, strategic alliances, distribution agreements, intellectual property advice, intellectual property litigation, regulatory advice and commercial advice.

 

ETV Capital is Europe's leading provider of venture debt and structured finance solutions for venture capital backed technology and healthcare businesses. Founded in 1999, ETV has a long track record of investing in companies in the UK, Ireland, France, Germany, Switzerland, Israel and the Nordic states.

 

GE Healthcare Financial Services offers innovative financing solutions to help early-stage life sciences companies extend their liquidity and raise further funds without diluting their equity. Their venture loan and venture lease products assist companies across the world from their first venture round to post-IPO. They are experienced in developing flexible solutions to meet customers' individual needs and improve their business' productivity and profitability.

 

Founded in 1991, Paul Capital Partners is not only an established member of the global private equity community, but is recognized as an industry innovator. They are a partner of choice, offering fair value, predictable liquidity, and well-tailored transactions, through three distinct areas of investment: Healthcare Royalty and Revenue Interests, Private Equity Secondaries and Top Tier Venture Funds.

 

Strategem IPM was formed in 1999 to fill a developing need within the biotechnology industry for strategic advice and management of intellectual property. They cover all aspects of the biotechnology, medical devices, diagnostic and pharmaceutical, material science, heavy & specialty chemicals, petrochemicals, polymers, engineering and high tech sectors.

 

Modern Biosciences is a drug development company that in-licenses late-stage discovery projects from academia and spin out companies. Our team of experts plan and execute a focused development program for the in-licensed asset. The resulting data package is intended to maximise the value of the asset prior to entering licensing negotiations with pharmaceutical or biotech partners.

 

Ernst & Young's Global Pharmaceutical Center brings together a worldwide team of professionals with deep experience in providing assurance, tax, transaction and advisory services to pharmaceutical companies around the globe. It's a team that works to anticipate market trends and their implications. So you get practical advice on the right way forward for your organization.